Alzheimer’s disease

Eisai and BioArctic’s Leqembi Iqlik, a subcutaneous formulation of lecanemab for Alzheimer’s, has been named one of TIME’s ‘Best Inventions of 2025’. This recognition highlights its potential in targeting amyloid-beta. Leqembi, developed through collaboration and based on BioArctic’s research, is approved in multiple countries for early Alzheimer’s. The subcutaneous option offers a more convenient administration route. Analysts predict this award may boost investor confidence in BioArctic and Eisai. BioArctic retains Nordic commercialization rights and receives milestone payments and royalties.

Algernon Pharmaceuticals (AGNPF) shareholders approved a new Series 1 Preferred Share class with a 10% annual dividend and convertibility into common shares. Following approval, the company will issue preferred shares and warrants related to past transactions. All board nominees were elected with over 95% approval. Algernon plans to rebrand as Algernon Health Inc., expanding into Alzheimer’s Disease diagnostics and neuroimaging clinics across North America, representing a strategic shift to diversify revenue streams.

Eisai, in partnership with BioArctic AB, is launching Leqembi in Europe, starting with Austria and Germany. Leqembi, approved by the European Commission in April 2025, is the first therapy targeting the underlying cause of Alzheimer’s disease (AD). Indicated for early AD patients (ApoE ε4 non-carriers or heterozygotes) with confirmed amyloid pathology, Leqembi demonstrated a 31% reduction in clinical decline in trials. Lecanemab selectively binds to aggregated soluble and insoluble forms of amyloid-beta (Aβ). It has already been approved in U.S., Japan, EU, China, etc. Common adverse reactions include infusion-related reactions and ARIA.

BioArctic’s Q2 2025 royalties surged to SEK 162.5 million due to strong Leqembi (lecanemab) sales, developed with Eisai, reaching JPY 23.1 billion. This included a one-time China stockpiling effect of JPY 5.3 billion. Excluding this, sales were JPY 17.8 billion, with royalties of approximately SEK 125 million. BioArctic will release its full Q2 report on August 28, focusing on Leqembi’s sustainable growth. Leqembi, targeting early Alzheimer’s, is approved in 46 countries and under review in 10 more.